Preclinical studies with new pyrrolidine platinum(II) compounds

F. Sampedro; VWT W.T. Ruiz van Haperen; MA A. Izquierdo; M. Vicens; P. Santaló; M. Pueyo; M. Llagostera; E. Marcuello; L. De Andrés

doi:10.1016/0223-5234(96)88260-2

Preclinical studies with new pyrrolidine platinum(II) compounds

F. Sampedro, VWT W.T. Ruiz van Haperen, MA A. Izquierdo, M. Vicens, P. Santaló, M. Pueyo, M. Llagostera, E. Marcuello, L. De Andrés

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

8 Cites (Scopus)

Resum

Four new platinum compounds containing different pyrrolidines as ligands are reported. In vitro tests show damage to bacterial DNA and participation of RecA protein in the repair system. In vitro tests using leukemia L1210 cells show growth inhibition by the new compounds within the range of cisplatin and carboplatin. In vivo tests using leukemia L1210 cells on male BDF1 show that these compounds are significantly active. © 1995 Elsevier, Paris.

Idioma original	Anglès
Pàgines (de-a)	497-501
Revista	European Journal of Medicinal Chemistry
Volum	30
Número	6
DOIs	https://doi.org/10.1016/0223-5234(96)88260-2
Estat de la publicació	Publicada - 1 de gen. 1995

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1016/0223-5234(96)88260-2

Altres arxius i enllaços

https://www.scopus.com/pages/publications/0029043258

Com citar-ho

@article{ce6a315345904fea82d81dcd1f536985,

title = "Preclinical studies with new pyrrolidine platinum(II) compounds",

abstract = "Four new platinum compounds containing different pyrrolidines as ligands are reported. In vitro tests show damage to bacterial DNA and participation of RecA protein in the repair system. In vitro tests using leukemia L1210 cells show growth inhibition by the new compounds within the range of cisplatin and carboplatin. In vivo tests using leukemia L1210 cells on male BDF1 show that these compounds are significantly active. {\textcopyright} 1995 Elsevier, Paris.",

keywords = "antitumoral activity, cancer treatment, growth, inhibition, L1210 leukemia, platinum(II) compound, platinum(II)-DNA damage, pyrrolidine, viability",

author = "F. Sampedro and \{Ruiz van Haperen\}, \{VWT W.T.\} and Izquierdo, \{MA A.\} and M. Vicens and P. Santal{\'o} and M. Pueyo and M. Llagostera and E. Marcuello and Andr{\'e}s, \{L. De\}",

year = "1995",

month = jan,

day = "1",

doi = "10.1016/0223-5234(96)88260-2",

language = "English",

volume = "30",

pages = "497--501",

number = "6",

}

TY - JOUR

T1 - Preclinical studies with new pyrrolidine platinum(II) compounds

AU - Sampedro, F.

AU - Ruiz van Haperen, VWT W.T.

AU - Izquierdo, MA A.

AU - Vicens, M.

AU - Santaló, P.

AU - Pueyo, M.

AU - Llagostera, M.

AU - Marcuello, E.

AU - Andrés, L. De

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Four new platinum compounds containing different pyrrolidines as ligands are reported. In vitro tests show damage to bacterial DNA and participation of RecA protein in the repair system. In vitro tests using leukemia L1210 cells show growth inhibition by the new compounds within the range of cisplatin and carboplatin. In vivo tests using leukemia L1210 cells on male BDF1 show that these compounds are significantly active. © 1995 Elsevier, Paris.

AB - Four new platinum compounds containing different pyrrolidines as ligands are reported. In vitro tests show damage to bacterial DNA and participation of RecA protein in the repair system. In vitro tests using leukemia L1210 cells show growth inhibition by the new compounds within the range of cisplatin and carboplatin. In vivo tests using leukemia L1210 cells on male BDF1 show that these compounds are significantly active. © 1995 Elsevier, Paris.

KW - antitumoral activity

KW - cancer treatment

KW - growth

KW - inhibition

KW - L1210 leukemia

KW - platinum(II) compound

KW - platinum(II)-DNA damage

KW - pyrrolidine

KW - viability

UR - https://www.scopus.com/pages/publications/0029043258

U2 - 10.1016/0223-5234(96)88260-2

DO - 10.1016/0223-5234(96)88260-2

M3 - Article

SN - 0223-5234

VL - 30

SP - 497

EP - 501

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

IS - 6

ER -

Preclinical studies with new pyrrolidine platinum(II) compounds

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho